文献速递骨软组织肉瘤与黑色素瘤

CheckMate 037:晚期黑色素瘤患者接受纳武利尤单抗与研究者选择化疗的总生存比较:一项随机、对照、开放标签III期试验

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
PubMed 文献 · J Clin Oncol · 2017-07-03

CheckMate 037研究纳入既往伊匹木单抗治疗后进展的晚期黑色素瘤患者,按2:1随机分配至纳武利尤单抗3 mg/kg每2周组或研究者选择化疗组。纳武利尤单抗组客观缓解率更高(27% vs 10%)、缓解持续时间更长(32个月 vs 13个月),但中位总生存无差异(16个月 vs 14个月;HR 0.95;95.54% CI 0.73-1.24)。

要点

  • 纳武利尤单抗组客观缓解率27% vs 研究者选择化疗组10%,中位缓解持续时间32个月 vs 13个月。
  • 中位总生存16个月 vs 14个月(HR 0.95;95.54% CI 0.73-1.24),无差异。
  • 纳武利尤单抗组3-4级治疗相关不良事件14% vs 研究者选择化疗组34%。

核心结论

  • 纳武利尤单抗与研究者选择化疗相比,缓解率更高、缓解更持久,但总生存无差异。
  • 总生存需谨慎解读,可能受随机分配后治疗前退出率增加导致化疗组交叉治疗、以及纳武利尤单抗组预后不良因素患者比例增加的影响。

研究设计与样本

  • 随机、对照、开放标签III期试验(CheckMate 037),纳入既往伊匹木单抗治疗后疾病进展的晚期黑色素瘤患者。
  • 按程序性死亡配体1表达、BRAF状态和既往细胞毒性T淋巴细胞抗原-4治疗最佳反应分层,2:1随机分配至纳武利尤单抗3 mg/kg静脉给药每2周组或研究者选择化疗组。
  • 研究者选择化疗为达卡巴嗪1,000 mg/m2每3周或卡铂曲线下面积6联合紫杉醇175 mg/m2每3周。
  • 治疗至疾病进展或不可接受毒性,随访约2年。
  • 272例随机分配至纳武利尤单抗组(99%接受治疗),133例随机分配至研究者选择化疗组(77%接受治疗)。

主要发现

  • 纳武利尤单抗组基线脑转移患者20% vs 研究者选择化疗组14%,乳酸脱氢酶升高者52% vs 38%。
  • 研究者选择化疗组41% vs 纳武利尤单抗组11%在随机分配治疗后接受抗程序性死亡1药物治疗。
  • 中位总生存:纳武利尤单抗组16个月 vs 研究者选择化疗组14个月(风险比0.95;95.54% CI 0.73-1.24)。
  • 中位无进展生存:纳武利尤单抗组3.1个月 vs 研究者选择化疗组3.7个月(风险比1.0;95.1% CI 0.78-1.436)。
  • 客观缓解率:纳武利尤单抗组27% vs 研究者选择化疗组10%;中位缓解持续时间:32个月 vs 13个月;3-4级治疗相关不良事件:14% vs 34%。

局限性

  • 总生存需谨慎解读,可能受随机分配后治疗前退出率增加导致研究者选择化疗组交叉治疗的影响。
  • 总生存可能受纳武利尤单抗组预后不良因素患者比例增加的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with ipilimumab. Here, we report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma. Patients and Methods Patients were stratified by programmed death-ligand 1 expression, BRAF status, and best prior cytotoxic T-lymphocyte antigen-4 therapy response, then randomly assigned 2:1 to nivolumab 3 mg/kg intravenously every 2 weeks or investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m2 every 3 weeks or carboplatin area under the curve 6 plus paclitaxel 175 mg/m2 every 3 weeks). Patients were treated until they experienced progression or unacceptable toxicity, with follow-up of approximately 2 years. Results Two hundred seventy-two patients were randomly assigned to nivolumab (99% treated) and 133 to ICC (77% treated). More nivolumab-treated patients had brain metastases (20% v 14%) and increased lactate dehydrogenase levels (52% v 38%) at baseline; 41% of patients treated with ICC versus 11% of patients treated with nivolumab received anti-programmed death 1 agents after randomly assigned therapy. Median OS was 16 months for nivolumab versus 14 months for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 months, respectively (hazard ratio, 1.0; 95.1% CI, 0.78 to 1.436). Overall response rate (27% v 10%) and median duration of response (32 months v 13 months) were notably higher for nivolumab versus ICC. Fewer grade 3 and 4 treatment-related adverse events were observed in patients on nivolumab (14% v 34%). Conclusion Nivolumab demonstrated higher, more durable responses but no difference in survival compared with ICC. OS should be interpreted with caution as it was likely impacted by an increased dropout rate before treatment, which led to crossover therapy in the ICC group, and by an increased proportion of patients in the nivolumab group with poor prognostic factors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Larkin J, Minor D, D'Angelo S, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2017. PMID: 28671856. doi:10.1200/JCO.2016.71.8023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。